<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107655">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998763</url>
  </required_header>
  <id_info>
    <org_study_id>KSCX2-EW-R-10-VDII</org_study_id>
    <secondary_id>KSCX2-EW-R-10</secondary_id>
    <nct_id>NCT01998763</nct_id>
  </id_info>
  <brief_title>Vitamin D Intervention Trial in Healthy Chinese,Phase II</brief_title>
  <official_title>Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To investigate the effects of vitamin D3 supplement on metabolic phenotypes including
           BMI, blood pressure, vitamin D metabolites, liver function, renal function and
           circulating mineral biomarkers;

        2. To determine the effects of genetic variants on bioavailability of vitamin D3
           supplements and its associations with metabolic phenotypes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention study will mainly investigate bioavailability and effects of vitamin D3
      supplements on metabolic traits, and also to what extent that genetic variants will modify
      effect of vitamin D3 supplements on 25(OH)D among the individuals with vitamin D deficiency.
      A total of 400 eligible subjects (200 in each group) will receive either vitamin D3
      supplements or placebo for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>25-hydroxyvitamin D</measure>
    <time_frame>0，12，24 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Serum 25(OH)D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1,25-dihydroxycholecalciferol</measure>
    <time_frame>0,12,24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum 1,25(OH)2D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24,25-Dihydroxycholecalciferol</measure>
    <time_frame>0,12,24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum 24,25(OH)2D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,24,25(OH)3D</measure>
    <time_frame>0,12,24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum 1,24,25(OH)3D concentration will be assayed by utilizing a liquid chromatography-mass spectrometry (LC-MS) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>parathyroid hormone</measure>
    <time_frame>0,12,24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D binding protein</measure>
    <time_frame>0,12,24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 placebo pills per day, 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 vitamin D3 pills per day, 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules have similar appearance and smell as 400IU vitamin D3 capsules,</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D2000 IU per day</description>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 20-45 years. with vitamin D deficiency or insufficiency (25(OH)D &lt; 75 nmol/l)

        Exclusion Criteria:

          -  BMI &lt; 18.5 kg/m2, or BMI ≥ 25 kg/m2

          -  Total intake of calcium from diet or supplements &gt;1200mg/d, or fasting serum calcium
             level ≥2.75 mmol/l

          -  Participating in other clinical studies within previous 3 months

          -  Taking vitamin D supplements within previous 3 months

          -  Using medications that may affect vitamin D metabolism in previous 3 months;

          -  Concomitant with clinical conditions, like liver dysfunction (serum alanine
             transaminase (ALT) ≥40 U/L; and/or aspartate transaminase (AST) ≥40 U/L; Glutamyl
             transpeptidase （GGT）≥50 U/L; serum creatinine &lt; 50 or &gt; 120 µmol/L; urea nitrogen
             (UN) &lt; 7 or &gt; 18 mg/dl, and/or urine acid &lt;90 or &gt;420 µmol/L; which may affect
             vitamin D metabolism;

          -  History of drug or alcohol abuse (&gt;40 g/d)

          -  Women during pregnancy or lactation

          -  Individuals with mental disorders or current use of antidepressants, the conditions
             which may affect him or her understanding and unwillingness to the intervention;

          -  Having clinically diagnosed AIDS, hepatitis A, hepatitis B, tuberculosis and other
             infectious diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu Lin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pang Yao</last_name>
    <phone>+86-21-54920972</phone>
    <email>yaopang@sibs.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Nutritional Sciecnes, Chinese Acadamy of Sciences</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pang Yao</last_name>
      <phone>+86-21-54920972</phone>
      <email>yaopang@sibs.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Xu Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Xu Lin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitamin D</keyword>
  <keyword>metabolite</keyword>
  <keyword>genotype</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
